CD47 and cancer: Combining temozolomide (a chemotherapeutic agent) and CD47 blocking agents, including antagonistic anti-CD47 monoclonal antibody (mAb) increases type 1 IFN production by activating cGAS/STING signaling in myeloid antigen-presenting cells (APCs)/MICs in different cancers [154–156].